Zydus introduces biosimilar Aflibercept 2 mg Anyra for advancing ophthalmic care

Zydus Lifesciences Ltd., an innovation-led global life sciences company, announced the launch of Anyra, India’s first indigenously developed biosimilar of Aflibercept 2 mg. Zydus has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer. Anyra is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion (Branch RVO or Central RVO), visual impairment due to diabetic macular edema (DME), diabetic retinopathy (DR), and visual impairment due to myopic choroidal neovascularization (mCNV). With this launch, Zydus reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.
 
Presently, more than 100 million people in India are living with diabetes, making it one of the largest diabetic populations globally. diabetic retinopathy (DR) affects an estimated 7–8 million individuals, with many progressing to vision-threatening stages such as DME. Wet AMD impacts approximately 1.5–2 million elderly patients, while retinal vein occlusions affect over 2 million individuals. Collectively, these conditions represent a large patient pool requiring timely anti-VEGF therapy to prevent irreversible vision loss. As chronic retinal diseases require repeated intravitreal injections over extended periods, affordability and continuity of treatment are of concern. Enhanced access to such therapies improves treatment adherence, reduces preventable blindness, and lowers long-term disease burden.
 
Speaking on the launch, Dr Sharvil P Patel, managing director, Zydus Lifesciences Ltd., said, “At Zydus, we are committed to making advanced biologics accessible to patients who need them most. ANYRA is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics. Our focus remains on enabling patient-centric outcomes by leveraging science, health and innovation.”
 
Zydus has India’s largest biosimilar portfolio with more than 13 biosimilars and complex biologic molecules developed and manufactured entirely in India. The company has established end-to-end capabilities across biologics development - from cell line research and process engineering to clinical trials, manufacturing, and regulatory approvals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!